Oso Biopharmaceuticals Manufacturing, LLC ("Oso
Biopharmaceuticals") and Catalent Pharma
Solutions today jointly announced the completion of the purchase of
Catalent´s Albuquerque, New Mexico sterile
injectables manufacturing business. Terms of the transaction, which
became effective May 17, were not disclosed. The Albuquerque business provides cGMP glass vial filling and
lyophilization services for injectable drugs and biologics that are
either approved for commercial marketing or in clinical development. Oso
Biopharmaceuticals will retain all employees associated with the
business and continue to serve all existing customers in North America
and Europe. Dr. Stuart Rose, Chief Executive Officer and President of Oso
Biopharmaceuticals, said, "We are delighted to
have been successful in acquiring Catalent´s sterile injectables
business based in Albuquerque. It fits exceedingly well with our
strategy to build a world class, high quality contract manufacturing
company. We will work tirelessly with the talent pool in Albuquerque to
meet the highest demands and expectations of our global customer base." Altaris Capital Partners, LLC ("Altaris")
a healthcare investment firm, collaborated with Oso Biopharmaceuticals
and provided capital for the transaction. Richard Yarwood, Group President of Sterile Technologies for Catalent
said, "We are pleased to have completed this
planned step in the evolution of our Sterile Technologies business. We
are also pleased that Oso Biopharmaceuticals has acquired this business
as we expect they will continue to provide the facility´s
customers the high degree of quality and compliance they have received
in the past. We also appreciate the commitment Oso Biopharmaceuticals
has demonstrated to the future of the business, and to the dedicated
employees at the site." About Oso Biopharmaceuticals Oso Biopharmaceuticals Manufacturing, LLC is a contract manufacturing
company focused on providing a superior level of service to customers.
With an emphasis on the production of injectable pharmaceutical products
that require special or complex handling, Oso Biopharmaceuticals
understands that attention to detail and service levels are a priority
for its clients. About Altaris Altaris Capital Partners, LLC is an investment firm focused exclusively
on companies operating in the healthcare industry. Altaris is based in
New York and has more than $750 million of assets under management. For
more information, please visit www.altariscap.com. About Catalent Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is one
of the leading providers of advanced technologies, and development
manufacturing and packaging services for pharmaceutical, biotechnology
and consumer healthcare companies in nearly 100 countries. Catalent
applies its local market expertise and technical creativity to advance
treatments, change markets and enhance patient outcomes. Catalent
employs approximately 10,000 at more than 30 facilities worldwide and
generates more than $1.7 billion of annual revenue. For more
information, visit www.catalent.com.
